Neuphoria Therapeutics Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Neuphoria Therapeutics Inc. (NEUP) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$350.42 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-09-18
- Neuphoria Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$222.14K, a 124.93% decline year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $584.96K, a 23992.22% increase year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$195.37K.
- Neuphoria Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$517.87K.
- Neuphoria Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2026 was -$350.42K, a 177.35% decline from fiscal 2025.
- Neuphoria Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $453.06K.
- Neuphoria Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$338.71K.
- Neuphoria Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$173.97K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$222.14K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $362.82K derived: sum of 2 quarters · filed 2026-09-18 | $167.45K derived: sum of 3 quarters · filed 2026-09-18 | -$350.42K 10-K · filed 2026-09-18 |
| 2026-03-31 | $584.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $389.59K derived: sum of 2 quarters · filed 2026-05-15 | -$128.28K 10-Q · filed 2026-05-15 | $762.65K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$195.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$713.24K 10-Q · filed 2026-02-17 | $177.69K derived: sum of 3 quarters · filed 2026-09-18 | $180.12K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$517.87K 10-Q · filed 2025-11-14 | $373.05K derived: sum of 2 quarters · filed 2026-09-18 | $375.48K derived: sum of 3 quarters · filed 2026-09-18 | $162.84K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $890.93K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $893.35K derived: sum of 2 quarters · filed 2026-09-18 | $680.72K derived: sum of 3 quarters · filed 2026-09-18 | $453.06K 10-K · filed 2026-09-18 |
| 2025-03-31 | $2.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$210.21K derived: sum of 2 quarters · filed 2026-05-15 | -$437.87K 10-Q · filed 2026-05-15 | -$612.31K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$212.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$440.30K 10-Q · filed 2026-02-17 | -$614.74K derived: sum of 3 quarters · filed 2026-02-17 | -$915.74K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$227.66K 10-Q · filed 2025-11-14 | -$402.10K derived: sum of 2 quarters · filed 2025-11-14 | -$703.10K derived: sum of 3 quarters · filed 2025-11-14 | -$139.05K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$174.44K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$475.44K derived: sum of 2 quarters · filed 2025-05-20 | $88.60K derived: sum of 3 quarters · filed 2025-05-20 | -$338.71K 10-K · filed 2024-09-30 |
| 2024-03-31 | -$301.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | $263.04K derived: sum of 2 quarters · filed 2025-05-20 | -$164.27K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $564.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $136.73K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$427.32K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$173.97K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |